Literature DB >> 24952228

Methods to detect non-compliance and reduce its impact on population PK parameter estimates.

Leonid Gibiansky1, Ekaterina Gibiansky, Valerie Cosson, Nicolas Frey, Franziska Schaedeli Stark.   

Abstract

This work proposes and evaluates two methods (CM1 and CM2) for detecting non-compliance using concentration-time data and for obtaining estimates of population pharmacokinetic model parameters in a population with prevalent non-compliance. CM1 estimates individual residual variability (RV) and identifies subjects with higher than average RV as non-compliant. Exclusion of subjects with high RV from the analysis dataset reduces the bias in the estimates of the model parameters. Various methods of identification and exclusion of non-compliant subjects were tested, compared, and shown to reduce or eliminate bias in parameter estimates associated with non-compliance. The tested methods were (i) a pre-defined cutoff value of the random effect on RV, (ii) sequential exclusion of subjects with the highest RV percentiles, and (iii) use of a mixture model for RV. CM2 is applicable for the data with a specific sampling pattern that includes a potentially non-compliant outpatient part with several trough samples followed by a dense profile after the inpatient (compliant) dose. It relies only on the doses known to be administered (e.g., inpatient doses). In this method, all concentration measurements during the outpatient part of the study (except the trough value immediately preceding the inpatient dose) are removed from the dataset and an additional parameter (individual relative bioavailability of the outpatient doses) is introduced. For a number of simulated datasets with various sampling schemes and non-compliance patterns the proposed methods allowed to identify subjects with compliance problems and to reduce or eliminate bias in the estimates of the model parameters.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24952228     DOI: 10.1007/s10928-014-9364-2

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  9 in total

1.  Population one-compartment pharmacokinetic analysis with missing dosage data.

Authors:  Dolors Soy; Stuart L Beal; Lewis B Sheiner
Journal:  Clin Pharmacol Ther       Date:  2004-11       Impact factor: 6.875

2.  Assumption testing in population pharmacokinetic models: illustrated with an analysis of moxonidine data from congestive heart failure patients.

Authors:  M O Karlsson; E N Jonsson; C G Wiltse; J R Wade
Journal:  J Pharmacokinet Biopharm       Date:  1998-04

3.  Do we need full compliance data for population pharmacokinetic analysis?

Authors:  P Girard; L B Sheiner; H Kastrissios; T F Blaschke
Journal:  J Pharmacokinet Biopharm       Date:  1996-06

4.  A Bayesian approach for the estimation of patient compliance based on the last sampling information.

Authors:  Olivier Barrière; Jun Li; Fahima Nekka
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-03-29       Impact factor: 2.745

5.  Selecting reliable pharmacokinetic data for explanatory analyses of clinical trials in the presence of possible noncompliance.

Authors:  J Lu; J M Gries; D Verotta; L B Sheiner
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-08       Impact factor: 2.745

6.  An alternative method for population pharmacokinetic data analysis under noncompliance.

Authors:  Pankaj Gupta; Matthew M Hutmacher; Bill Frame; Raymond Miller
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-02-26       Impact factor: 2.745

7.  An integrated multiple-analyte pharmacokinetic model to characterize trastuzumab emtansine (T-DM1) clearance pathways and to evaluate reduced pharmacokinetic sampling in patients with HER2-positive metastatic breast cancer.

Authors:  Dan Lu; Amita Joshi; Bei Wang; Steve Olsen; Joo-Hee Yi; Ian E Krop; Howard A Burris; Sandhya Girish
Journal:  Clin Pharmacokinet       Date:  2013-08       Impact factor: 6.447

8.  The impact of patient compliance on drug concentration profile in multiple doses.

Authors:  W Wang; F Husan; S C Chow
Journal:  Stat Med       Date:  1996-03-30       Impact factor: 2.373

9.  Estimation of population pharmacokinetic parameters in the presence of non-compliance.

Authors:  Song Mu; Thomas M Ludden
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-02       Impact factor: 2.745

  9 in total
  6 in total

1.  A pharmacometric case study regarding the sensitivity of structural model parameter estimation to error in patient reported dosing times.

Authors:  Jonathan Knights; Shashank Rohatagi
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-07-26       Impact factor: 2.745

2.  Tenofovir Plasma Concentration from Preexposure Prophylaxis at the Time of Potential HIV Exposure: a Population Pharmacokinetic Modeling and Simulation Study Involving Serodiscordant Couples in East Africa.

Authors:  Surulivelrajan Mallayasamy; Ayyappa Chaturvedula; Michael J Fossler; Mark Sale; Vineet Goti; Namandje N Bumpus; Mark A Marzinke; Craig W Hendrix; Jessica E Haberer
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

3.  Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202.

Authors:  Cindy J Bednasz; Charles S Venuto; Qing Ma; Eric S Daar; Paul E Sax; Margaret A Fischl; Ann C Collier; Kimberly Y Smith; Camlin Tierney; Edward P Acosta; Donald E Mager; Gene D Morse
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

Review 4.  Population Pharmacokinetics of Tacrolimus in Transplant Recipients: What Did We Learn About Sources of Interindividual Variabilities?

Authors:  Olivia Campagne; Donald E Mager; Kathleen M Tornatore
Journal:  J Clin Pharmacol       Date:  2018-10-29       Impact factor: 3.126

5.  Development and application of an aggregate adherence metric derived from population pharmacokinetics to inform clinical trial enrichment.

Authors:  Jonathan Knights; Shashank Rohatagi
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-03-29       Impact factor: 2.745

6.  Approaches to handling missing or "problematic" pharmacology data: Pharmacokinetics.

Authors:  Donald J Irby; Mustafa E Ibrahim; Anees M Dauki; Mohamed A Badawi; Sílvia M Illamola; Mingqing Chen; Yuhuan Wang; Xiaoxi Liu; Mitch A Phelps; Diane R Mould
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.